Renaissance Technologies LLC lowered its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS – Get Rating) by 22.7% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,514,800 shares of the company’s stock after selling 444,300 shares during the period. Renaissance Technologies LLC owned about 0.73% of Hims & Hers Health worth $8,453,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also made changes to their positions in HIMS. State Street Corp increased its position in shares of Hims & Hers Health by 147.8% during the second quarter. State Street Corp now owns 2,597,684 shares of the company’s stock worth $11,768,000 after purchasing an additional 1,549,546 shares in the last quarter. Nuveen Asset Management LLC increased its position in shares of Hims & Hers Health by 300.2% during the third quarter. Nuveen Asset Management LLC now owns 2,001,695 shares of the company’s stock worth $11,170,000 after purchasing an additional 1,501,568 shares in the last quarter. Northern Trust Corp increased its position in shares of Hims & Hers Health by 325.9% during the second quarter. Northern Trust Corp now owns 1,078,712 shares of the company’s stock worth $4,886,000 after purchasing an additional 825,405 shares in the last quarter. Jupiter Asset Management Ltd. acquired a new stake in shares of Hims & Hers Health during the third quarter worth about $1,244,000. Finally, Bank of America Corp DE increased its position in shares of Hims & Hers Health by 670.7% during the first quarter. Bank of America Corp DE now owns 222,911 shares of the company’s stock worth $1,188,000 after purchasing an additional 193,989 shares in the last quarter. Institutional investors and hedge funds own 45.60% of the company’s stock.
Hims & Hers Health Trading Down 3.0 %
Hims & Hers Health stock opened at $9.77 on Wednesday. The stock has a market cap of $2.04 billion, a PE ratio of -30.53 and a beta of 0.49. The stock has a 50-day moving average price of $8.27 and a 200 day moving average price of $6.66. Hims & Hers Health, Inc. has a 52 week low of $2.72 and a 52 week high of $12.04.
Insider Buying and Selling
In other Hims & Hers Health news, Director Alex Bard sold 500,000 shares of Hims & Hers Health stock in a transaction dated Wednesday, March 1st. The stock was sold at an average price of $11.55, for a total value of $5,775,000.00. Following the completion of the sale, the director now owns 296,878 shares in the company, valued at approximately $3,428,940.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Hims & Hers Health news, insider Soleil Boughton sold 50,000 shares of Hims & Hers Health stock in a transaction dated Tuesday, January 31st. The stock was sold at an average price of $8.14, for a total value of $407,000.00. Following the completion of the sale, the insider now owns 237,089 shares in the company, valued at approximately $1,929,904.46. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Alex Bard sold 500,000 shares of Hims & Hers Health stock in a transaction dated Wednesday, March 1st. The shares were sold at an average price of $11.55, for a total value of $5,775,000.00. Following the completion of the sale, the director now owns 296,878 shares of the company’s stock, valued at approximately $3,428,940.90. The disclosure for this sale can be found here. In the last quarter, insiders sold 582,625 shares of company stock worth $6,404,157. 35.22% of the stock is owned by corporate insiders.
Analysts Set New Price Targets
Several equities analysts recently issued reports on HIMS shares. Citigroup boosted their price target on Hims & Hers Health from $9.00 to $14.00 and gave the company a “buy” rating in a research report on Tuesday, February 28th. Credit Suisse Group boosted their price target on Hims & Hers Health from $8.00 to $14.00 and gave the company an “outperform” rating in a research report on Wednesday, March 1st. Bank of America boosted their price target on Hims & Hers Health from $11.50 to $13.50 and gave the company a “buy” rating in a research report on Tuesday, February 28th. Guggenheim reiterated a “buy” rating and set a $15.00 target price on shares of Hims & Hers Health in a research report on Tuesday, February 28th. Finally, Deutsche Bank Aktiengesellschaft boosted their target price on Hims & Hers Health from $7.00 to $9.00 in a research report on Wednesday, March 1st. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $11.55.
Hims & Hers Health Company Profile
Hims & Hers Health, Inc operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care.
Featured Stories
- Get a free copy of the StockNews.com research report on Hims & Hers Health (HIMS)
- Under-the-Radar Azul SA Takes Flight on Robust Travel Demand
- Market Gets “Powelled”: S&P 500 Confirms Resistance
- Rivian Plummets, But Is This 2023’s Greatest Buying Opportunity?
- Ulta Insiders Hold Tight: Sell-Siders Buy
- Potential Earnings Have Rated Ambrx Biopharma a Moderate Buy
Want to see what other hedge funds are holding HIMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hims & Hers Health, Inc. (NYSE:HIMS – Get Rating).
Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.
